Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | MPI | P34949 | 2/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.41 |
| ▸ | PMM2 | O15305 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28760046 | 0.79 | KDM4E (0.50) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL15984839 | 0.76 | HCRTR1 (0.44) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL19380463 | 0.75 | KDM4E (0.50) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL17051399 | 0.74 | KMT2A (0.44) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL13052936 | 0.73 | KDM4E (0.52) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL961773 | 0.72 | HTT (0.59) | MEN1KMT2AMAPTHSD17B10POLB | |
| SCHEMBL1876393 | 0.71 | KDM4E (0.43) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL2666269 | 0.71 | CYP3A4 (0.42) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL13806030 | 0.71 | SORD (0.55) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL7904079 | 0.71 | SORD (0.55) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1832584-B1 | PYRIMIDINYLISOXAZOLE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-7939536-B2 | 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20080114003-A1 | Pyrimidinylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1832584-A1 | PYRIMIDINYLISOXAZOL DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2007-09-12 | — | — | EP | disclosed |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1383760-A1 | BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002090347-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | KDM4E 2600/4885ALDH1A1 2901/4885GAA 2694/4885 |
| US-20080114003-A1 | Pyrimidinylisoxazole Derivatives | MAPK3, MAPK7, MAP3K7 | KDM4E 1483/4885ALDH1A1 2957/4885GAA 4255/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | KDM4E 2286/4885ALDH1A1 1603/4885GAA 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.